Tags

Type your tag names separated by a space and hit enter

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.
Curr Radiopharm. 2018; 11(3):200-208.CR

Abstract

Background

Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.

Objective and Conclusion

This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.

Links

PMC Free PDF

Authors+Show Affiliations

Morgenstern A
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Apostolidis C
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.
Kratochwil C
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Sathekge M
Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
Krolicki L
Department of Nuclear Medicine, Medical University Warsaw, Warsaw, Poland.
Bruchertseifer F
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

MeSH

ActiniumAlpha ParticlesBismuthClinical Trials as TopicHumansNeoplasmsRadiochemistryRadioimmunotherapyRadioisotopesRadiopharmaceuticals

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29732998

Citation

Morgenstern, Alfred, et al. "An Overview of Targeted Alpha Therapy With 225Actinium and 213Bismuth." Current Radiopharmaceuticals, vol. 11, no. 3, 2018, pp. 200-208.
Morgenstern A, Apostolidis C, Kratochwil C, et al. An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11(3):200-208.
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L., & Bruchertseifer, F. (2018). An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. Current Radiopharmaceuticals, 11(3), 200-208. https://doi.org/10.2174/1874471011666180502104524
Morgenstern A, et al. An Overview of Targeted Alpha Therapy With 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11(3):200-208. PubMed PMID: 29732998.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. AU - Morgenstern,Alfred, AU - Apostolidis,Christos, AU - Kratochwil,Clemens, AU - Sathekge,Mike, AU - Krolicki,Leszek, AU - Bruchertseifer,Frank, PY - 2017/12/11/received PY - 2018/01/18/revised PY - 2018/03/06/accepted PY - 2018/5/8/pubmed PY - 2019/1/12/medline PY - 2018/5/8/entrez KW - Targeted alpha therapy KW - actinium-225 KW - alpha emitter KW - bismuth-213 KW - clinical application KW - nuclide production. SP - 200 EP - 208 JF - Current radiopharmaceuticals JO - Curr Radiopharm VL - 11 IS - 3 N2 - Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer. SN - 1874-4729 UR - https://www.unboundmedicine.com/medline/citation/29732998/ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓139 ↑41]

Related Citations

    More

    Others Viewed